{"id":255,"date":"2016-10-18T16:16:26","date_gmt":"2016-10-18T16:16:26","guid":{"rendered":"https:\/\/halopharma.com\/about-2\/leadership\/"},"modified":"2026-05-05T12:52:58","modified_gmt":"2026-05-05T16:52:58","slug":"leadership","status":"publish","type":"page","link":"https:\/\/halopharma.com\/fr\/who-we-are\/leadership\/","title":{"rendered":"Direction"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"Lee-Karras-1-480x669\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Lee Karras<\/h4>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t
CEO of Halo Pharma<\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tLinkedIn<\/span>\n\t\t\t\t\t\t<\/path><\/svg>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Mr. Karras assumed the role of Group CEO at Halo Pharma in May 2026, following its spin out from the Noramco Group as a standalone drug product CDMO. He previously served as Group Chief Executive Officer of the Noramco Group an API business which was sold to Siegfried in May 2026. Prior to his leadership at Noramco, he was a Director at SK Capital Partners, where he provided operational, sales, and general management guidance to various healthcare portfolio companies. Mr. Karras previously served as President of IBA Molecular North America (also an SK Capital Partners portfolio company) that was sold to Illinois Health and Sciences in 2015. Before IBA, Mr. Karras was President and CEO of AAIPharma Services Company where he led the company\u2019s transition from bankruptcy to a successful exit in 2009. Prior to AAI, Lee held various positions at Baxter Healthcare and Cook Medical (Cook and Baxter Pharmaceutical Solutions), where he served as General Manager and helped build the pharmaceutical services start up into a sizable sterile injectable pharma services business.<\/p>

Lee est titulaire d'une licence en chimie de l'Universit\u00e9 de l'Indiana \u00e0 Bloomington et d'une ma\u00eetrise en sciences de l'environnement de l'\u00c9cole des affaires publiques et environnementales de l'Universit\u00e9 de l'Indiana \u00e0 Bloomington.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"IMG_8448\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Laurent Malgouyres\n<\/h4>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t
Directeur de site
Mirabel, Qu\u00e9bec<\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tLinkedIn<\/span>\n\t\t\t\t\t\t<\/path><\/svg>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Laurent Malgouyres est directeur du site de Halo Pharma \u00e0 Mirabel, au Qu\u00e9bec, o\u00f9 il supervise la production, la qualit\u00e9 et la performance globale du site. Il a rejoint Halo Pharma en 2025 apr\u00e8s avoir occup\u00e9 le poste de vice-pr\u00e9sident des op\u00e9rations chez Omega Laboratories\/Juno Pharmaceuticals au Canada.<\/p>

Fort de plus de 14 ans d'exp\u00e9rience dans l'industrie pharmaceutique, Laurent a pr\u00e9c\u00e9demment occup\u00e9 des postes de direction chez Pharmascience, o\u00f9 il a g\u00e9r\u00e9 des sites agr\u00e9\u00e9s par la FDA et Sant\u00e9 Canada employant plus de 200 personnes. Tout au long de sa carri\u00e8re, il a pilot\u00e9 des initiatives visant \u00e0 accro\u00eetre les capacit\u00e9s de production, \u00e0 am\u00e9liorer l'efficacit\u00e9 op\u00e9rationnelle et \u00e0 mener \u00e0 bien d'importants projets d'investissement.<\/p>

Laurent est titulaire d'une licence en physique (ITEC) et d'un dipl\u00f4me universitaire en chimie de l'universit\u00e9 Paul Sabatier en France.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"A\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Ruben Ortiz\n<\/h4>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t
Directeur g\u00e9n\u00e9ral
Halo Whippany<\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tLinkedIn<\/span>\n\t\t\t\t\t\t<\/path><\/svg>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Ruben est reconnu comme un leader strat\u00e9gique et transformationnel, fort de plus de trente ans d'exp\u00e9rience dans l'industrie pharmaceutique. Son expertise r\u00e9side dans la fabrication de produits pharmaceutiques et le d\u00e9veloppement de m\u00e9dicaments. Il ma\u00eetrise la rem\u00e9diation des syst\u00e8mes qualit\u00e9, la planification de la cha\u00eene d'approvisionnement, la gestion du changement et la gestion de projet, et poss\u00e8de une solide exp\u00e9rience des plateformes d'excellence op\u00e9rationnelle. Ruben a perfectionn\u00e9 ses comp\u00e9tences de leadership en collaborant avec des g\u00e9ants de l'industrie tels que Merck, J&J, Pfizer, Wyeth, Watson et Schering-Plough, entre autres.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Lee Karras CEO of Halo Pharma Linkedin Mr. Karras assumed the role of Group CEO at Halo Pharma in May 2026, following its spin out from the Noramco Group as a standalone drug product CDMO. He previously served as Group Chief Executive Officer of the Noramco Group an API business which was sold to Siegfried […]<\/p>\n","protected":false},"author":25,"featured_media":0,"parent":3362,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-255","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages\/255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=255"}],"version-history":[{"count":50,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages\/255\/revisions"}],"predecessor-version":[{"id":4049,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages\/255\/revisions\/4049"}],"up":[{"embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages\/3362"}],"wp:attachment":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}